Muscle Damage
Conditions
Brief summary
The primary goal of this investigation is to assess whether Solarplast (R) supplementation will improve recovery following heavy resistance exercise in active adults. The primary questions to be addressed are: Does Solarplast (R) decrease muscle damage and inflammation associated with heavy resistance exercise? Does Solarplast (R) reduce the decline in performance associate with heavy resistance exercise? Researchers will compare Solarplast (R) to a placebo (a look-alike substance that contains no active ingredients) to see if Solarplast (R) is effective at improving recovery. Participants will be asked to: Take Solarplast (R) or placebo daily for 4 weeks Visit the laboratory at least once per week to receive their supplement Report to the lab for 3 consecutive visits following supplementation to complete a heavy resistance training session and follow-up testing.
Interventions
DIETARY_SUPPLEMENTSolarplast (R)
Daily supplementation for 28 days prior to heavy resistance exercise.
DIETARY_SUPPLEMENTPlacebo
Daily supplementation for 28 days prior to heavy resistance exercise.
Sponsors
Kent State University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Recreationally-active (participated in at least 2 weight training workouts per week over the previous year) and participates in at least 3h of total structured exercise/week as determined by the health and activity questionnaire. * Subject is judged by the Investigator to be healthy and free of any physical limitations (determined by health and activity questionnaire) * Subject has a body mass index of 18.0-34.9 kg/m2, inclusive * Subject is willing to maintain habitual diet throughout the study period * Subject is willing to abstain from dietary supplementation throughout the duration of the study. * Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigators
Exclusion criteria
* Subject is currently or will be enrolled in another clinical trial. * Subject is a habitual consumer of tea/antioxidants defined as \> 8 oz/day of either green or black tea within the 14 days prior to the screening visit. * Subject has a history or presence of a clinically relevant cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder. * Subject has a history or presence of cancer in the prior 2 years, except for non-melanoma skin cancer. * Subject is unable to perform physical exercise (determined by health and activity questionnaire) * Subject is engaged in an extreme diet including but not limited to, Atkins, South Beach, Intermittent Fasting, etc. * Subject is allergic to the study product or placebo * Subject is taking any other nutritional supplement or performance enhancing drug (determined from health and activity questionnaire) * Subject has any chronic illness that causes continuous medical care * Taking any type of prescription or over-the-counter medication including but not limited to corticosteroids, non-steroidal anti-inflammatory drugs, and antibiotics within the 14 days prior to the screening visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Creatine Kinase Activity | Acute changes following exercise for 48 hours | Marker of Muscle Damage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vertical Jump Height | Acute changes following exercise for 48 hours | Measure of Performance Change |
| Mean Squat Velocity | Acute changes following exercise for 48 hours | Measure of Performance Change |
| Peak Isometric Muscle Force | Acute changes following exercise for 48 hours | Measure of Performance Change |
| Myoglobin Concentration | Acute changes following exercise for 24 hours | Marker of Muscle Damage |
| Ratings of Perceived Fatigue | Acute changes following exercise for 48 hours | Visual Analog Scale (1-100mm; low values indicated reduced fatigue) |
| Ratings of Perceived Soreness | Acute changes following exercise for 48 hours | Visual Analog Scale (1-100mm; low values indicate reduced soreness) |
| Rate of Force Development | Acute changes following exercise for 48 hours | Measure of Performance Change |
Other
| Measure | Time frame | Description |
|---|---|---|
| Rate of Force Development | Change in Resting Values over 4 weeks of supplementation | Measure of Performance Change |
| Rate of Muscular Fatigue | Acute changes following exercise for 48 hours | Measure of Performance Change |
| Vertical Jump Height | Change in Resting Values over 4 weeks of supplementation | Measure of Performance Change |
| Peak Muscle Force | Acute changes following exercise for 48 hours | Measure of Performance Change |
| Lactate Dehydrogenase Activity | Acute changes following exercise for 48 hours | Marker of Muscle Damage |
| Cortisol Concentration | Acute changes following exercise for 48 hours | Circulating Marker of Stress |
| Glutathione (GSH) Activity | Change in Resting Values over 4 weeks of supplementation | Circulating Marker of Oxidative Stress |
| Total Antioxidant Capacity | Change in Resting Values over 4 weeks of supplementation | Circulating Marker of Oxidative Stress |
| Interleukin 6 (IL-6) Concentration | Change in Resting Values over 4 weeks of supplementation | Circulating Marker of Inflammation |
| Interleukin 10 (IL-10) Concentration | Change in Resting Values over 4 weeks of supplementation | Circulating Marker of Inflammation |
| Tumor Necrosis Factor - alpha (TNFa) Concentration | Change in Resting Values over 4 weeks of supplementation | Circulating Marker of Inflammation |
Countries
United States
Contacts
Primary ContactAdam R Jajtner, PhD
Outcome results
None listed